CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 4 enrolled
Drug / intervention
Rifaximin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02470780
NCT02470780Phase 3Completed
CompareCT.gov

Treating Bacterial Overgrowth in Parkinson's Disease

University of Cincinnati·interventional·Posted Jun 12, 2015·Updated Mar 1, 2024

In Brief

A Phase 3 clinical trial evaluating Rifaximin and Placebo for Parkinson's Disease and Small Intestinal Bacterial Overgrowth. Completed, enrolled 4 participants across 1 site.

Detailed Summary

This study investigates the effect of treating Small Intestinal Bacterial Overgrowth (SIBO) in patients with Parkinson's Disease (PD). It will test the hypothesis that treating SIBO with the antibiotic rifaximin will improve motor complications in previously SIBO-positive PD patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease, Small Intestinal Bacterial Overgrowth
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 12, 2015
Enrollment StartDec 1, 2015
Primary CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.1 years ago

Interventions

Rifaximindrug

Rifaximin is an antibiotic used to treat SIBO. It is a 7-day course of treatment followed by three or six months of follow-up. This is a placebo-controlled study designed so that all participants will receive the active drug at least once during the study.

Placebodrug

Placebo matching Rifaximin treatment.